Guardant Health (GH)
(Delayed Data from NSDQ)
$21.40 USD
+0.79 (3.83%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $21.38 -0.02 (-0.09%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$21.40 USD
+0.79 (3.83%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $21.38 -0.02 (-0.09%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum D VGM
Zacks News
3 Cancer Treatment Stocks to Enrich Your Portfolio
by Tirthankar Chakraborty
Investments in cancer therapies are expected to rise almost $250 billion by 2023, from $150 billion in 2018. Thus, companies that are coming up with innovative methods to cure this malaise are great investment choices.
AMAG Q2 Loss Widens, Sales Lag Estimates, 2019 Guidance Cut
by Zacks Equity Research
AMAG Pharmaceuticals (AMAG) reports wider-than-expected loss and sales miss in the second quarter of 2019. The company lowers its 2019 view.
Arena Pharmaceuticals' (ARNA) Q2 Loss Widens, Revenues Meet
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) incurs wider-than-expected loss in the second quarter of 2019 while revenues are in line.
Has Guardant Health (GH) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (GH) Outperforming Other Medical Stocks This Year?
Top Ranked Momentum Stocks to Buy for August 5th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, August 5th
Guardant Health (GH) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Guardant Health (GH) will provide updates on Guardant360 and GuardantOMNI tests during the second-quarter 2019 earnings call.
The Zacks Analyst Blog Highlights: Invitae, Illumina, Pacific Biosciences and Guardant Health
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Invitae, Illumina, Pacific Biosciences and Guardant Health
46 and You: Genetic Testing = Giant Growth Market
by Kevin Cook
Advances in genomic diagnostic technology have made testing affordable for the 99.0% of the world still in line.
The Zacks Analyst Blog Highlights: Guardant, Illumina, Exact Sciences and Pfizer
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Guardant, Illumina, Exact Sciences and Pfizer
Guardant Health (GH) Looks Good: Stock Adds 6% in Session
by Zacks Equity Research
Guardant Health (GH) saw a big move last session, as its shares jumped 6% on the day, amid huge volumes.
3 Stocks to Win Big in the Fight Against Cancer
by Tirthankar Chakraborty
We highlight three stocks that are using innovative ways to treat cancer, also called malignancy. These stocks are also great long-term investments.
Drug/Biotech Stock Q1 Earnings on May 9: IONS, XLRN & More
by Zacks Equity Research
Five drug/biotech stocks are scheduled to release their first-quarter results on May 9. Let's take a look at how these companies are poised ahead of their earnings release.
Guardant Health (GH) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
At Guardant Health's (GH) Q1 conference, investors will watch out for the updates on liquid biopsy-based Guardant360 and GuardantOMNI tests that could help detect advanced stages of cancer.
Guardant Health (GH) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Guardant Health (GH) closed at $66.12, marking a -1.9% move from the previous day.